Humulin N

Humulin N is a prescription injectable suspension containing insulin human (NPH) as its active ingredient. It is supplied in a standardized concentration for subcutaneous administration and is marketed in the European Union. As a basal insulin, Humulin N provides prolonged glucose‑lowering activity to help maintain blood‑sugar control in patients with diabetes mellitus. The formulation is designed for dosing and is intended for use under the guidance of a healthcare professional.

Humulin N is indicated for the long‑term management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus (insulin‑dependent). - Type 2 diabetes mellitus when basal insulin is required. - Adjunct to rapid‑acting insulin analogues for basal‑bolus regimens. - Use during pregnancy only when benefits outweigh risks (under medical supervision). - May be employed in patients transitioning from other intermediate‑acting insulins. - Part of intensive insulin therapy protocols for hospitalized patients with hyperglycemia.

Adverse reactions to Humulin N may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy presenting as localized fat accumulation or loss. - Transient weight gain related to improved glycemic control.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Insulin antibody formation leading to unpredictable glucose response.

When prescribing or using Humulin N, clinicians and patients should consider several precautionary measures to minimize risks.

- Assess renal and hepatic function, as impairment can prolong insulin action. - Adjust dose during periods of illness, stress, or changes in physical activity. - Monitor blood glucose closely when initiating therapy or modifying the regimen. - Use lower initial doses in elderly patients to reduce hypoglycemia risk. - Avoid use in patients with known hypersensitivity to insulin human or any excipients. - Counsel patients on proper injection technique to prevent lipohypertrophy. - Review pregnancy status; insulin requirements may change during gestation.

Humulin N can interact with other medications that affect glucose metabolism or insulin pharmacodynamics, requiring dose adjustments or monitoring.

Avoid: - Concurrent use of other insulin products or concentrated insulin formulations without appropriate dose reduction. - Co‑administration with sulfonylureas or meglitinides that may precipitate severe hypoglycemia.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms; monitor glucose more frequently. - Corticosteroids and thiazide diuretics can increase insulin resistance, potentially requiring higher doses. - Oral contraceptives or hormone replacement therapy may alter insulin requirements.